ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,463.54
      0.08%
      US Tech 100
      18,493.20
      -0.14%
      Dow Jones
      40,539.93
      -0.12%
      Brent Oil
      78.885
      -0.33%
      Bitcoin
      66,384.61
      -0.66%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Sagiment Biosciences Inc (SGMT) Quote

      Sagiment Biosciences Inc

      Sagiment Biosciences Inc (SGMT)

      NASDAQ
      3.35
      -0.07
      (-2.05%)
      Closed July 29 4:00PM
      Delayed by 15 minutes
      3.35
      -0.04
      (-1.18%)
      After Hours: 6:56PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      3.35
      Bid
      3.33
      Ask
      3.35
      Volume
      198,292
      3.32 Day's Range 3.52
      2.13 52 Week Range 20.71
      Market Cap
      101.818M
      Previous Close
      3.42
      Open
      3.47
      Last Trade
      1
      @
      3.33
      Last Trade Time
      Financial Volume
      $ 684,092
      VWAP
      3.4499
      Average Volume (3m)
      535,179
      Shares Outstanding
      30,393,397
      Dividend Yield
      -
      PE Ratio
      -3.70
      Earnings Per Share (EPS)
      -0.92
      Revenue
      2M
      Net Profit
      -27.88M

      About Sagiment Biosciences Inc

      Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment ... Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.sagimet.com
      Headquarters
      Camden, Delaware, USA
      Founded
      1970
      Sagiment Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SGMT. The last closing price for Sagiment Biosciences was $3.42. Over the last year, Sagiment Biosciences shares have traded in a share price range of $ 2.13 to $ 20.71.

      Sagiment Biosciences currently has 30,393,397 shares outstanding. The market capitalization of Sagiment Biosciences is $103.95 million. Sagiment Biosciences has a price to earnings ratio (PE ratio) of -3.70.

      SGMT Latest News

      More News

      FeaturedCannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA

      12 hours ago

      Form 4 - Statement of changes in beneficial ownership of securities

      July 25 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      July 23 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      July 23 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      July 23 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      July 23 2024
      Edgar (US Regulatory)

      Form 8-K/A - Current report: [Amend]

      June 13 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 07 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 07 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      June 06 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.278.766233766233.083.55532.952310043.27902777CS
      4-0.05-1.470588235293.43.712.783839723.19552232CS
      12-1.03-23.51598173524.385.72.785351794.18004005CS
      26-8.15-70.869565217411.511.762.788002425.65360421CS
      52-12.55-78.930817610115.920.712.136563259.15979395CS
      156-12.15-78.387096774215.520.712.136361899.23869982CS
      260-12.15-78.387096774215.520.712.136361899.23869982CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      TWOU2U Inc
      $ 2.70
      (116.00%)
      		139.18M
      LIPOLipella Pharmaceuticals Inc
      $ 0.8576
      (112.22%)
      		194.69M
      NIPGNIP Group Inc
       16.50
      (82.93%)
      		7.04M
      TIVCTivic Health Systems Inc
      $ 0.7049
      (55.95%)
      		106.15M
      ISPOInspirato Inc
      $ 5.15
      (47.99%)
      		6.24M
      CGTXCognition Therapeutics Inc
      $ 1.32
      (-44.30%)
      		26.32M
      GRIGRI Bio Inc
      $ 0.8334
      (-33.86%)
      		1.14M
      CEROCERo Therapeutics Holdings Inc
      $ 0.1817
      (-29.02%)
      		8.28M
      PRSTPresto Technologies Inc
      $ 0.0499
      (-26.51%)
      		29.32M
      TGLTreasure Global Inc
      $ 1.40
      (-24.32%)
      		80.79k
      NVDANVIDIA Corporation
      $ 111.59
      (-1.30%)
      		248.03M
      LIPOLipella Pharmaceuticals Inc
      $ 0.8576
      (112.22%)
      		194.69M
      SQQQProShares UltraPro Short QQQ
      $ 9.05
      (-0.55%)
      		152.03M
      TWOU2U Inc
      $ 2.70
      (116.00%)
      		139.18M
      TSLATesla Inc
      $ 232.10
      (5.60%)
      		129.2M

      SGMT Discussion

      View Posts
      Pip611 Pip611 4 weeks ago
      Anyone know why this has been tanking so bad the last couple weeks?
      👍️0
      Monksdream Monksdream 3 months ago
      SGMT under $5
      👍️0
      AGORDON AGORDON 5 months ago
      Sagimet Biosciences (Nasdaq: SGMT $6.25)
      Buy recommendation.

      Market cap = $199M
      Cash = $210M+ (Just raised $112M through a secondary offering)
      Estimated cash burn = ($25)/year
      Lead product = Denifanstat an oral, once daily pill and selective first-in-class FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
      Jan. 22, 2024 announced positive topline results from Phase 2b clinical trial of Denifanstat in Biopsy-confirmed F2/FS NASH.
      The results are comparable to Madrigal's Resmitiron.
      Ascletis collaboration agreement = Potential $122M in milestone payments as well as tiered royalties ranging from percentages in the high single digits to mid-teens on future net sales of Denifanstat, which is referred to as ASC40 in Greater China
      Most AEs (adverse events) were Grade 1 or 2 (mild to moderate). There were no Grade 3 AEs.
      👍️0
      eneels01 eneels01 6 months ago
      See if $10 level holds. MC could drift upward later this year towards $1B area as company is similar to ETNB…
      👍️0
      dinogreeves dinogreeves 6 months ago
      Yup, got out at 16.25, thought they had enough in the coffers to push through this year. It was a good score while it lasted.
      👍️0
      TheFinalCD TheFinalCD 6 months ago
      Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
      https://newsfilter.io/articles/sagimet-biosciences-announces-pricing-of-public-offering-of-series-a-common-stock-c3511595df124183e48b41923f34e655

      Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
      https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-announces-proposed-public-offering-series
      👍️0
      gail gail 6 months ago
      congrats!
      👍️0
      dinogreeves dinogreeves 6 months ago
      Only down 5% for after hours. Nothing to sweat over.
      👍️0
      dinogreeves dinogreeves 6 months ago
      Three nice winners in my circle.
      👍️0
      dinogreeves dinogreeves 6 months ago
      Looks like another run tomorrow.
      👍️0
      gail gail 6 months ago
      that was fun! i love “bar charts as…

      …

      ” i get a lot of good leads from that free website.
      👍️0
      gail gail 6 months ago
      hey dino, looks like we got a runner here, weeeee!!
      👍️0
      gail gail 6 months ago
      grabbed a few on the dip. hi all.
      👍️0
      dinogreeves dinogreeves 6 months ago
      Looks like easy 500% gainer today.
      👍️0
      dinogreeves dinogreeves 6 months ago
      What a great move and Baker Brothers in it, I simply got lucky at 11.38 with 2500 shares. Looks like billion dollar market cap is going to fetched here real soon.
      👍️0
      Awl416 Awl416 6 months ago
      That 20k block they filled at 9.69 before ripping

      Yummy
      👍️0
      Awl416 Awl416 6 months ago
      Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
      👍️0

      Your Recent History

      NASDAQ
      SGMT
      Sagiment Biosciences
      BIT
      F17169
      Vontobel Financial Produ...
      NASDAQ
      AAXBVXX
      JPMorgan Chase Financial...
      FX
      DKKUSD
      DKK vs US Dollar
      LSE
      QUT
      Quester Vct 4
      Delayed Upgrade Clock